Answers are grounded in this paper and cite their sources.
analyses of participants with type 2 diabetes mellitus (T2DM) but no baseline CKD in other trials, indicates that SGLT2 inhibitor treatment will benefit an expanded CKD population with diverse baseline albuminuria or eGFR values, presence of T2DM or cause of CKD, as well as providing primary prevention of CKD in at least the T2DM setting.
No takes yet. Share an insight, caveat, or question.
Fernández‐Fernández et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: